home · filing · 0000950170-24-051383
8-K filed May 1, 2024, 7:59 PM ET
ticker AKTX
CIK 0001541157
leadership
confidence high
sentiment negative
materiality 0.80
Akari Therapeutics CEO and COO exit; merger portfolio prioritizes ADC and GA over other programs
Akari Therapeutics Plc
Rachelle Jacques stepped down as CEO effective May 1; COO Melissa Bradford-Klug terminated without cause same date.
Board member Samir Patel appointed interim CEO; compensated $50k monthly in RSUs.
Interim CFO DiCicco gets $40k/month, 45% bonus, transaction bonus, and 1% RSU grant.
Merger with Peak Bio to focus on ADC platform (TROP-2) and PAS-nomacopan for Geographic Atrophy.
HSCT-TMA program suspended, PHP 303 discontinued; merger expected close Q3 2024.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Departed
Melissa Bradford-Klug
Chief Operating Officer
AKTX ·
Akari Therapeutics Plc
Effective 2024-05-01
Filed May 1, 2024, 7:59 PM ET
our Chief Operating Officer, Melissa Bradford-Klug, was terminated without cause, effective May 1, 2024.
Effective 2024-05-01
Successor Samir R. Patel
Filed May 1, 2024, 7:59 PM ET
Rachelle Jacques stepped down as the President and Chief Executive Officer of Akari Therapeutics, Plc (the “Company”), effective May 1, 2024.
Effective 2024-05-01
Filed May 1, 2024, 7:59 PM ET
the Board appointed Samir R. Patel, M.D., a member of the Board, to Interim President and Chief Executive Officer, effective May 1, 2024
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Melissa Bradford-Klug departed as Chief Operating Officer at Akari Therapeutics Plc.
Action terminated without cause
Role Chief Operating Officer
Exact text from the filing
our Chief Operating Officer, Melissa Bradford-Klug, was terminated without cause, effective May 1, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Rachelle Jacques departed as President and Chief Executive Officer at Akari Therapeutics Plc.
Action stepped down
Role President and Chief Executive Officer
Exact text from the filing
Rachelle Jacques stepped down as the President and Chief Executive Officer of Akari Therapeutics, Plc (the “Company”), effective May 1, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Samir R. Patel was appointed as Interim President and Chief Executive Officer at Akari Therapeutics Plc.
Action appointed
Role Interim President and Chief Executive Officer
Exact text from the filing
the Board appointed Samir R. Patel, M.D., a member of the Board, to Interim President and Chief Executive Officer, effective May 1, 2024
View on SEC.gov
Source: SEC EDGAR
accession 0000950170-24-051383
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.